This is the authors' abstract. We don't add key points for this paper.
There is no consensus if we should consider OSA as a single disease with different phenotypes with or without EDS, or if there are different diseases with different genetic/epigenetic determinants, pathogenic mechanisms, prognosis, and treatment.The small number of studies focused on this issue indicates the need for further research in this area. Clinicians must carefully assess the presence or absence of EDS and decide accordingly the treatment. This approach could improve combination therapy targeted to a patient's specific pathology to enhance both efficacy and long-term adherence to OSA treatment and significantly reduce the social, economic, and health negative impact of OSA.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Garbarino et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: